Overview

Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy

Status:
Unknown status

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate if the combination of Lpv/r monotherapy and anti-HCV drugs does not match with additional toxicity induced by the association of HAART and Peg-IFN + ritonavir in patients naive for HIV and HCV. Secondary objective is to assess if Lpv/r monotherapy during HCV-treatment is associated with HIV efficacy vs optimized HAART.

Phase:

Phase 3

Details

Lead Sponsor:

IRCCS San Raffaele

Collaborators:

Abbott
Hoffmann-La Roche

Treatments:

Hepatitis C Antibodies
Interferon-alpha
Lopinavir
Peginterferon alfa-2a
Reverse Transcriptase Inhibitors
Ribavirin
Ritonavir